



**EISAI RECEIVES PREQUALIFICATION FROM WORLD HEALTH ORGANIZATION
FOR LYMPHATIC FILARIASIS MEDICINE DIETHYLCARBAMAZINE
*SUPPLY FROM VIZAG PLANT, INDIA TO 24 ENDEMIC COUNTRIES TO BEGIN THIS YEAR***

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received prequalification from the World Health Organization (WHO) for diethylcarbamazine citrate (DEC) 100 mg tablets manufactured at its Vizag Plant in India for the treatment of lymphatic filariasis, a n worldwide, which poses a major obstacle in eliminating the disease. As part of Eisai's commitment under the declaration, the company has agreed to produce 2.2 billion high-quality DEC tablets at the Vizag Plant and, from 2013, to work with WHO to supply the tablets at price zero to endemic countries over a

[Notes to editors]

1. About Neglected Tropical Diseases (NTDs)

According to the World Health Organization (WHO), NTDs blight the lives of more

4. About the WHO Prequalification of Medicines Programme

The WHO Prequalification Medicines Programme aims to make quality medicines available for the treatment of high-priority diseases. Medicinal products submitted for prequalification are comprehensively evaluated based on information provided by the manufacturers and inspection of the corresponding manufacturing and clinical sites, with those products that are recognized as having met the WHO quality standard subsequently placed on a list of prequalified medicinal products used by United Nations agencies and other organizations to guide their procurement decisions regarding medicines being provided to the developing world.